The Harvard University, while addressing the risk associated with reactions of new drugs prescription, has stated some overwhelming facts. According to their findings, even properly prescribed drugs causes about 1.9 million hospitalizations a year and about 128,000 people die from drugs prescribed to them.[1] Such epidemic condition is being tailgated by the need of safe and effective and specific use of the drug. Owing to such demands, companion diagnostic drug market is poised for exponential growth. Companion diagnostics is an in-vitro diagnostic tool that assists physicians in optimizing treatment decisions for their patients and is crucial for myriad of cancer and other therapies. Riding on the back of economic burden of global healthcare and with abundant potential to restrict the liability, companion diagnostic market size is estimated to be $2,950 million as of 2018. Companion Diagnostic Market Outlook: Companion diagnostic (CDx) is a diagnostic test used as an associate to a ...